http://orcid.org/0000-0002-7344-8995
References
- Bihari C, Rastogi A, Saxena P, et al. Parvovirus B19 associated hepatitis. Hepat Res Treat. 2013;2013:472027.
- Gowland P, Fontana S, Stolz M, et al. Parvovirus B19 passive transmission by transfusion of Intercept® blood system-treated platelet concentrate. Transfus Med Hemother. 2016;43:198–202.
- Palabrica FRR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac Allergy. 2013;3:249–256.
- Markvardsen LH, Christiansen I, Andersen H, et al. Headache and nausea after treatment with high-dose subcutaneous versus intravenous immunoglobulin. Basic Clin Pharmacol Toxicol. 2015;117:409–412.
- Melamed RI, Gupta S, Bobbitt MS, et al. Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases. Clin Exp Immunol. 2016;184:228–236.
- Piguet D, Tosi C, Lüthi JM, et al. Redimune® NF liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions. Clin Exp Immunol. 2008;152:45–49.
- Azizi G, Abolhassani H, Asgardoon MH, et al. Managing patients with side effects and adverse events to immunoglobulin therapy. Expert Rev Clin Pharmacol. 2016;9:91–102.